Tim Wright, global head of development of Swiss drugmaker Novartis, smiles after a Reuters interview in Basel December 5, 2013. Swiss drugmaker Novartis is developing a treatment that stimulates ... more 
Tim Wright, global head of development of Swiss drugmaker Novartis, smiles after a Reuters interview in Basel December 5, 2013. Swiss drugmaker Novartis is developing a treatment that stimulates muscle growth in sufferers. It is betting that the drug, known as bimagrumab or BYM338 and developed with German biotech company MorphoSys, might help combat muscle loss associated with conditions like cancer and chronic lung disease that affect millions of people. Picture taken December 5, 2013. To match NOVARTIS-MUSCLEWASTING/DRUG REUTERS/Arnd Wiegmann (SWITZERLAND - Tags: HEALTH HEADSHOT DRUGS SOCIETY BUSINESS) less 
1 / 30
Reuters | Photo By ARND WIEGMANN / REUTERS
Sat, Dec 7, 2013 2:34 AM EST